Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.04
AMRS's Cash to Debt is ranked lower than
95% of the 1020 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.59 vs. AMRS: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
AMRS' s 10-Year Cash to Debt Range
Min: 0.04  Med: 1.44 Max: N/A
Current: 0.04
Equity to Asset -1.41
AMRS's Equity to Asset is ranked lower than
99% of the 870 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.53 vs. AMRS: -1.41 )
Ranked among companies with meaningful Equity to Asset only.
AMRS' s 10-Year Equity to Asset Range
Min: -1.41  Med: 0.25 Max: 0.87
Current: -1.41
-1.41
0.87
F-Score: 2
Z-Score: -7.47
M-Score: -6.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -235.01
AMRS's Operating margin (%) is ranked lower than
97% of the 999 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 5.56 vs. AMRS: -235.01 )
Ranked among companies with meaningful Operating margin (%) only.
AMRS' s 10-Year Operating margin (%) Range
Min: -312.41  Med: -230.69 Max: -98.14
Current: -235.01
-312.41
-98.14
Net-margin (%) -178.71
AMRS's Net-margin (%) is ranked lower than
97% of the 1000 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.04 vs. AMRS: -178.71 )
Ranked among companies with meaningful Net-margin (%) only.
AMRS' s 10-Year Net-margin (%) Range
Min: -571.78  Med: -121.69 Max: 5.28
Current: -178.71
-571.78
5.28
ROA (%) -35.03
AMRS's ROA (%) is ranked lower than
96% of the 1024 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 3.76 vs. AMRS: -35.03 )
Ranked among companies with meaningful ROA (%) only.
AMRS' s 10-Year ROA (%) Range
Min: -106.46  Med: -55.57 Max: 1.1
Current: -35.03
-106.46
1.1
ROC (Joel Greenblatt) (%) -1.15
AMRS's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 1017 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 10.82 vs. AMRS: -1.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.97  Med: -158.14 Max: 25.82
Current: -1.15
-297.97
25.82
Revenue Growth (3Y)(%) -52.10
AMRS's Revenue Growth (3Y)(%) is ranked lower than
98% of the 809 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 3.70 vs. AMRS: -52.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMRS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -53.95 Max: -52.1
Current: -52.1
» AMRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AMRS Guru Trades in

AMRS Guru Trades in

Q2 2013

AMRS Guru Trades in Q2 2013

Paul Tudor Jones 11,600 sh (unchged)
» More
Q3 2013

AMRS Guru Trades in Q3 2013

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 4.39
AMRS's P/S is ranked lower than
83% of the 989 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.99 vs. AMRS: 4.39 )
Ranked among companies with meaningful P/S only.
AMRS' s 10-Year P/S Range
Min: 0.52  Med: 3.83 Max: 9.69
Current: 4.39
0.52
9.69
Current Ratio 0.66
AMRS's Current Ratio is ranked lower than
92% of the 887 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.72 vs. AMRS: 0.66 )
Ranked among companies with meaningful Current Ratio only.
AMRS' s 10-Year Current Ratio Range
Min: 0.54  Med: 1.83 Max: 11.36
Current: 0.66
0.54
11.36
Quick Ratio 0.46
AMRS's Quick Ratio is ranked lower than
91% of the 887 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.18 vs. AMRS: 0.46 )
Ranked among companies with meaningful Quick Ratio only.
AMRS' s 10-Year Quick Ratio Range
Min: 0.37  Med: 1.48 Max: 11.22
Current: 0.46
0.37
11.22
Days Inventory 134.79
AMRS's Days Inventory is ranked lower than
88% of the 975 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 65.39 vs. AMRS: 134.79 )
Ranked among companies with meaningful Days Inventory only.
AMRS' s 10-Year Days Inventory Range
Min: 11.23  Med: 25.99 Max: 139.58
Current: 134.79
11.23
139.58
Days Sales Outstanding 25.72
AMRS's Days Sales Outstanding is ranked higher than
85% of the 837 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 58.83 vs. AMRS: 25.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRS' s 10-Year Days Sales Outstanding Range
Min: 7.75  Med: 20.68 Max: 73.27
Current: 25.72
7.75
73.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.98
AMRS's Price/Median PS Value is ranked higher than
70% of the 906 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.11 vs. AMRS: 0.98 )
Ranked among companies with meaningful Price/Median PS Value only.
AMRS' s 10-Year Price/Median PS Value Range
Min: 0.33  Med: 1.06 Max: 2.56
Current: 0.98
0.33
2.56
Earnings Yield (Greenblatt) (%) -0.29
AMRS's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 1004 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.80 vs. AMRS: -0.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMRS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -54.4  Med: 0.00 Max: 0
Current: -0.29
-54.4
0

Analyst Estimate

Dec15
EPS($) -0.90
EPS without NRI($) -0.90

Business Description

Industry: Chemicals » Specialty Chemicals
Compare: » details
Traded in other countries:3A0.Germany,
Amyris Inc was incorporated in California on July 17, 2003 and reincorporated in Delaware on June 10, 2010. The Company is a renewable products company engaged in providing sustainable alternatives to petroleum-sourced products. It developed microbial engineering and screening technologies that modify the way microorganisms process sugars. The Company is engaged in in developing various products to address five identified markets: cosmetics, flavors and fragrances, performance materials, lubricants and transportation fuels. The Company is using its proprietary synthetic biology platform to design microbes, mainly yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons. The Company is developing, and, in some cases, already commercializing, products from these hydrocarbons in several target markets, including cosmetics, lubricants, flavors and fragrances, performance materials, and transportation fuels. It calls these No Compromise products because it designs them to perform comparably to currently available products. The Company's first commercialization efforts have been focused on a renewable hydrocarbon molecule called farnesene Biofene, which forms the basis for various products varying from specialty chemical applications to transportation fuels, such as diesel. In addition, the Company has entered into various contract manufacturing agreements to support commercial production. The Company has established two main operating subsidiaries, Amyris Brasil Ltda. for production in Brazil, and Amyris Fuels, LLC. As of January 31, 2014, the Company had 247 issued U.S. and foreign patents and 327 pending U.S. and foreign patent applications that are owned by or licensed to it. The Company is subject to a various federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the United States, Brazil and other countries where it operates.
» More Articles for AMRS

Headlines

Articles On GuruFocus.com
Insiders Top Buys: Amyris Inc. Aug 07 2015 
Weekly CEO Sells Highlight: Netlist Inc, LifePoint Hospitals Inc, Amyris Inc, and Sapient Corp. May 25 2014 
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
Weekly CFO Sells Highlight: SCHW, TIBX, IL, AMRS, BCR, CCOI, CBST Apr 24 2011 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 

More From Other Websites
Amyris Set to Increase Global Growth of Its Cosmetic Emollients Through ISO 22716 Certification Sep 02 2015
Amyris Achieves Breakthrough Performance With 2nd Fragrance Molecule Ready for Industrial Scale... Aug 31 2015
Amyris Achieves Breakthrough Performance With 2nd Fragrance Molecule Ready for Industrial Scale... Aug 31 2015
AMYRIS, INC. Financials Aug 21 2015
10-Q for Amyris, Inc. Aug 13 2015
Amyris & Genome Compiler Launch Testing Program for Pharma and Biotech Companies to Explore DNA... Aug 11 2015
Amyris Reports Second Quarter 2015 Financial Results Aug 11 2015
Biossance™ Brand Announces The Launch Of The Embodied Project, A Four Week Program To Help Women... Aug 11 2015
Amyris & Genome Compiler Launch Testing Program for Pharma and Biotech Companies to Explore DNA... Aug 10 2015
AMYRIS, INC. Files SEC form 10-Q, Quarterly Report Aug 10 2015
Edited Transcript of AMRS earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 07 2015
AMYRIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2015
Amyris Reports Second Quarter 2015 Financial Results Aug 06 2015
5 Stocks Under $10 to Trade for Breakouts Aug 06 2015
Q2 2015 Amyris Inc Earnings Release - After Market Close Aug 06 2015
Amyris Announces Signing of Agreements for Conversion and Restructuring of Approximately $175... Aug 03 2015
Amyris Announces Closings of Conversion and Restructuring of Approximately $175 Million of... Aug 03 2015
Amyris to Announce Second Quarter Financial Results on Thursday, August 6, 2015 Aug 03 2015
Amyris to Present at Jefferies 11th Annual Industrials Conference on August 10, 2015 Aug 03 2015
AMYRIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Jul 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK